Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7344754

C=CCOc1c(OC)ccc2ccc(/C=N\N)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.41
POLB P06746 3/20 0.41
HSD17B10 Q99714 2/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
PLAU P00749 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
HSP90AA1 P07900 1/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 2/20 0.36
DNMT1 P26358 1/20 0.36
CCR6 P51684 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7344763 1.00 KDM4E (0.41) KDM4EPOLBHSD17B10SMN1; SMN2PLAU
Trifluoroacetic Acid SCHEMBL7337424 0.88 PLAU (0.46) KDM4EPOLBSMN1; SMN2PLAUALDH1A1
Trifluoroacetic Acid SCHEMBL7336995 0.88 PLAU (0.46) KDM4EPOLBSMN1; SMN2PLAUALDH1A1
Trifluoroacetic Acid SCHEMBL7345787 0.87 PLAU (0.55) KDM4EPOLBHSD17B10SMN1; SMN2PLAU
Trifluoroacetic Acid SCHEMBL7345802 0.87 PLAU (0.55) KDM4EPOLBHSD17B10SMN1; SMN2PLAU
Trifluoroacetic Acid SCHEMBL7334991 0.86 PLAU (0.41) KDM4EPOLBSMN1; SMN2PLAUL3MBTL1
Trifluoroacetic Acid SCHEMBL7334981 0.86 PLAU (0.41) KDM4EPOLBSMN1; SMN2PLAUL3MBTL1
Trifluoroacetic Acid SCHEMBL7344757 0.82 PLAU (0.62) KDM4EPOLBSMN1; SMN2PLAUALDH1A1
Trifluoroacetic Acid SCHEMBL7334801 0.77 KDM4E (0.36) KDM4EPOLBHSD17B10SMN1; SMN2PLAU
SCHEMBL7855504 0.73 PLAU (0.60) KDM4EHSD17B10SMN1; SMN2PLAUL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 KDM4E 4285/4885POLB 1129/4885HSD17B10 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.